Form 8-K - Current report:
SEC Accession No. 0000950103-25-009701
Filing Date
2025-08-01
Accepted
2025-08-01 16:25:24
Documents
15
Period of Report
2025-08-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dp232462_8k.htm   iXBRL 8-K 42979
2 EXHIBIT 4.1 dp232462_ex0401.htm EX-4.1 1348517
3 EXHIBIT 10.1 dp232462_ex1001.htm EX-10.1 1663112
4 EXHIBIT 10.2 dp232462_ex1002.htm EX-10.2 1776607
  Complete submission text file 0000950103-25-009701.txt   5942509

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE amrx-20250801.xsd EX-101.SCH 3008
6 XBRL LABEL FILE amrx-20250801_lab.xml EX-101.LAB 34239
7 XBRL PRESENTATION FILE amrx-20250801_pre.xml EX-101.PRE 22354
17 EXTRACTED XBRL INSTANCE DOCUMENT dp232462_8k_htm.xml XML 3576
Mailing Address 400 CROSSING BOULEVARD 3RD FLOOR BRIDGEWATER NJ 08807
Business Address (908) 947-3120
Amneal Pharmaceuticals, Inc. (Filer) CIK: 0001723128 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)